Can gene delivery close the door to HIV-1 entry after escape?

Journal of Medical Primatology

Volumn 35, Issue 4-5, 2006, Pages 236-247

  Swan, C H ^a   Torbett, Bruce E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antagonist; CCR5; CXCR4; Gene delivery; HIV 1; Viral entry

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 [1 [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4 METHYL 4 PIPERIDINYL] 2 METHYL 1 [1 [4 (TRIFLUOOROMETHYL)PHENYL]ETHYL]PIPERAZINE; AMD 070; AMD 887; APLAVIROC; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GSK 873; KRH 2731; KRH 3140; KRH 3955; MARAVIROC; RIBOZYME; SCH 41769; TAK 652; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; DRUG EFFICACY; DRUG TARGETING; GENE DISRUPTION; GENE TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; MICE; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA INTERFERENCE; RNA, CATALYTIC; ZINC FINGERS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33745943955     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2006.00172.x     Document Type: Article

References (119)

1. Ajuebor MN, Aspinall AI, Zhou F, Le T, Yang Y, Urbanski SJ, Sidobre S, Kronenberg M, Hogaboam CM, Swain MG: Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells. J Immunol 2005; 174:8027-37.
2. Alwin S, Gere MB, Guhl E, Effertz K, Barbas CF, III., Segal DJ, Weitzman MD, Cathomen T: Custom zinc-finger nucleases for use in human cells. Mol Ther 2005; 12:610-7.
3. Anderson J, Akkina R: HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther 2005; 2:1-12.
4. Anderson J, Banerjea A, Akkina R: Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 2003; 13:303-12.
5. Anderson J, Banerjea A, Planelles V, Akkina R: Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retroviruses 2003; 19:699-706.
6. Ank N, Petersen K, Malmgaard L, Mogensen SC, Paludan SR: Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2. J Virol 2005; 79:9831-41.
7. Arrighi JF, Pion M, Garcia E, Escola JM, van Kooyk Y, Geijtenbeek TB, Piguet V: DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J Exp Med 2004; 200:1279-88.
8. Bai J, Banda N, Lee NS, Rossi J, Akkina R: RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol Ther 2002; 6:770-82.
9. Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, Akkina R: Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 2000; 1:244-54.
10. Bai J, Rossi J, Akkina R: Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy. AIDS Res Hum Retroviruses 2001; 17:385-99.
11. Bai X, Chen JD, Yang AG, Torti F, Chen SY: Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines. Gene Ther 1998; 5:984-94.
12. Baltimore D: Gene therapy. Intracellular immunization. Nature 1988; 335:395-6.
13. Barber CG: CCR5 antagonists for the treatment of HIV. Curr Opin Investig Drugs 2004; 5:851-61.
14. Barr EL, Ouburg S, Igietseme JU, Morre SA, Okwandu E, Eko FO, Ifere G, Belay T, He Q, Lyn D, Nwankwo G, Lillard J, Black CM, Ananaba GA: Host inflammatory response and development of complications of Chlamydia trachomatis genital infection in CCR5-deficient mice and subfertile women with the CCR5delta32 gene deletion. J Microbiol Immunol Infect 2005; 38:244-54.
15. Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.
16. Besnier C, Takeuchi Y, Towers G: Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A 2002; 99:11920-5.
17. Butticaz C, Ciuffi A, Munoz M, Thomas J, Bridge A, Pebernard S, Iggo R, Meylan P, Telenti A: Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression. Antivir Ther 2003; 8:373-7.
18. Cameron P, Pope M, Granelli-Piperno A, Steinman RM: Dendritic cells and the replication of HIV-1. J Leukoc Biol 1996; 59:158-71.
19. Cameron PU, Freudenthal PS, Barker JM, Gezelter S, Inaba K, Steinman RM: Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 1992; 257:383-7.
20. Cameron PU, Pope M, Gezelter S, Steinman RM: Infection and apoptotic cell death of CD4+ T cells during an immune response to HIV-1-pulsed dendritic cells. AIDS Res Hum Retroviruses 1994; 10:61-71.
21. Carr DJ, Ash J, Lane TE, Kuziel WA: Abnormal immune response of CCR5-deficient mice to ocular infection with herpes simplex virus type 1. J Gen Virol 2006; 87:489-99.
22. Chatterji U, Bobardt MD, Stanfield R, Ptak RG, Pallansch LA, Ward PA, Jones MJ, Stoddart CA, Scalfaro P, Dumont JM, Besseghir K, Rosenwirth B, Gallay PA: Naturally occuring capsid substitutions render HIV-1 cyclophilin a independent in human cells and trim-cyclophilin resistant in owl monkey cells. J Biol Chem 2005; 280:40293-300.
23. Chen SY, Bagley J, Marasco WA: Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum Gene Ther 1994; 5:595-601.
24. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR: Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621-8.
25. Cordelier P, Kulkowsky JW, Ko C, Matskevitch AA, McKee HJ, Rossi JJ, Bouhamdan M, Pomerantz RJ, Kari G, Strayer DS: Protecting from R5-tropic HIV: Individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther, 2004; 11:1627-37.
26. Couzin J: Molecular biology. RNAi shows cracks in its armor. Science 2004; 306:1124-5.
27. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz PD: Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A 2002; 99:11914-9.
28. de Veer MJ, Sledz CA, Williams BR: Detection of foreign RNA: implications for RNAi. Immunol Cell Biol 2005; 83:224-8.
29. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.
30. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-6.
31. Doherty EA, Doudna JA: Ribozyme structures and mechanisms. Annu Rev Biophys Biomol Struct 2001; 30:457-75.
32. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price DA, Connors M, Koup RA: HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95-8.
33. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73.
34. Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, Chandrasegaran S: Zinc finger nucleases: Custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res 2005; 33:5978-90.
35. Engel BC, Bauer G, Pepper KA, Bockstoce DC, Yu XJ, Chen SY, Kohn DB: Intrakines - evidence for a trans-cellular mechanism of action. Mol Ther 2000; 1:165-70.
36. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872-7.
37. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100:587-97.
38. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM: Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005; 202:1087-98.
39. Goser S, Ottl R, Brodner A, Dengler TJ, Torzewski J, Egashira K, Rose NR, Katus HA, Kaya Z: Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 2005; 112:3400-7.
40. Gummuluru S, KewalRamani VN, Emerman M: Dendritic cell-mediated viral transfer to T cells is required for human immunodeficiency virus type 1 persistence in the face of rapid cell turnover. J Virol 2002; 76:10692-701.
41. Hanawa H, Hematti P, Keyvanfar K, Metzger ME, Krouse A, Donahue RE, Kepes S, Gray J, Dunbar CE, Persons DA, Nienhuis AW: Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 2004; 103:4062-9.
42. Hardison JL, Wrightsman RA, Carpenter PM, Kuziel WA, Lane TE, Manning JE: The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi. Infect Immun 2006; 74:135-43.
43. Hatziioannou T, Perez-Caballero D, Cowan S, Bieniasz PD: Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. J Virol 2005; 79:176-83.
44. Hernandez-Lopez C, Varas A, Sacedon R, Jimenez E, Munoz JJ, Zapata AG, Vicente A: Stromal cell-derived factor 1/CXCR4 signaling is critical for early human T-cell development. Blood 2002; 99:546-54.
45. High KA:TGene therapy: the moving finger. Nature 2005; 435:577-9.
46. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S, Hartmann G: Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11:263-70.
47. Idemyor V: Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: Are they the next novel therapies ? HIV Clin Trials 2005; 6:272-7.
48. Jackson AL, Linsley OS: Noise amidst the silence: off-target effects of siRNAs ? Trends Genet 2004; 20:521-4.
49. Johnson PR, Hirsch VM: SIV infection of macaques as a model for AIDS pathogenesis. Int Rev Immunol 1992; 8:55-63.
50. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23:457-62.
51. Kawabata K, Ujikawa M, Egawa T, Kawamoto H, Tachibana K, Iizasa H, Katsura Y, Kishimoto T, Nagasawa T: A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. Proc Natl Acad Sci U S A 1999; 96:5663-7.
52. Kontermann RE: Intrabodies as therapeutic agents. Methods 2004; 34:163-70.
53. Kozak SL, Platt EJ, Madani N, Ferro FE, Jr., Peden K, Kabat D: CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 1997; 71:873-82.
54. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT, Wolinsky SM, Moore JP: Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78:2790-807.
55. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR: DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 2002; 16:135-44.
56. LaBonte JA, Babcock GJ, Patel T, Sodroski J: Blockade of HIV-1 infection of New World monkey cells occurs primarily at the stage of virus entry. J Exp Med 2002; 196:431-45.
57. Lapidot T: Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. Ann N Y Acad Sci 2001; 938:83-95.
58. Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J, Akkina R, Rossi JJ: Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12:900-9.
59. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367-77.
60. Lobato MN, Rabbitts TH: Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol Med 2003; 9:390-6.
61. Lore K, Smed-Sorensen A, Vasudevan J, Mascola JR, Koup RA: Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med 2005; 201:2023-33.
62. Lu M, Grove EA, Miller RJ: Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc Natl Acad Sci U S A 2002; 99:7090-5.
63. Ma B, Kang MJ, Lee CG, Chapoval S, Liu W, Chen Q, Coyle AJ, Lora JM, Picarella D, Homer RJ, Elias JA: Role of CCR5 in IFN-gamma-induced and cigarette smoke-induced emphysema. J Clin Invest 2005; 115:3460-72.
64. Ma Q, Jones D, Borghesani PR, Segal RA, Nagasawa T, Kishimoto T, Bronson RT, Springer TA: Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A 1998; 95:9448-53.
65. Mani M, Kandavelou K, Dy FJ, Durai S, Chandrasegaran S: Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun 2005; 335:447-57.
66. Marasco WA, LaVecchio J, Winkler A: Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J Immunol Methods 1999; 231:223-38.
67. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, Clotet B, Este JA: Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. Aids 2002; 16:2385-90.
68. Milsom MD, Fairbairn LJ: Protection and selection for gene therapy in the hematopoietic system. J Gene Med 2004; 6:133-46.
69. Molyneaux KA, Zinszner H, Kunwar PS, Schaible K, Stebler J, Sunshine MJ, O'Brien W, Raz E, Littman D, Wylie C, Lehmann R: The chemokine SDF1/ CXCL12 and its receptor CXCR4 regulate mouse germ cell migration and survival. Development 2003; 130:4279-86.
70. Moreno C, Gustot T, Nicaise C, Quertinmont E, Nagy N, Parmentier M, Le Moine O, Deviere J, Louis H: CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 2005; 42:854-62.
71. Morris KV, Rossi JJ: Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther 2006; 13:553-8.
72. Munk C, Brandt SM, Lucero G, Landau NR: A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci U S A 2002; 99:13843-8.
73. Nie Y, Waite J, Brewer F, Sunshine MJ, Littman DR, Zou YR: The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med 2004; 200:1145-56.
74. Nisole S, Lynch C, Stoye JP, Yap MW: A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci U S A 2004; 101:13324-8.
75. O'Brien SJ, Moore JP: The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000; 177:99-111.
76. Ometto L, Bertorelle R, Mainardi M, Zanchetta M, Tognazzo S, Rampon O, Ruga E, Chieco-Bianchi L, De Rossi A: Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children. J Infect Dis 2001; 183:814-8.
77. Owens CM, Song B, Perron MJ, Yang PC, Stremlau M, Sodroski J: Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J Virol 2004; 78:5423-37.
78. Plotkin J, Prockop SE, Lepique A, Petrie HT: Critical role for CXCR4 signaling in progenitor localization and T cell differentiation in the postnatal thymus. J Immunol 2003; 171:4521-7.
79. Qin XF, An DS, Chen IS, Baltimore D: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003; 100:183-8.
80. Reeves JD, Piefer AJ: Emerging drug targets for antiretroviral therapy. Drugs 2005; 65:1747-66.
81. Richard E, Geronimi F, Lalanne M, Ged C, Redonnet-Vernhet I, Lamrissi-Garcia I, Gerson SL, de Verneuil H, Moreau-Gaudry F: A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines. J Gene Med 2003; 5:737-47.
82. Robbins MA, Rossi JJ: Sensing the danger in RNA. Nat Med 2005; 11:250-1.
83. Rossi JJ: The application of ribozymes to HIV infection. Curr Opin Mol Ther 1999; 1:316-22.
84. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M: Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5.
85. Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 2004; 430:569-73.
86. Schroers R, Davis CM, Wagner HJ, Chen SY: Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection. Gene Ther 2002; 9:889-97.
87. ShiotA M, Sano M, Miyagishi M, Taira K: Ribozymes: applications to functional analysis and gene discovery. J Biochem (Tokyo) 2004; 136:133-47.
88. Sioud M: Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol 2005; 348:1079-90.
89. Song B, Javanbakht H, Perron M, Park DH, Stremlau M, Sodroski J: Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. J Virol 2005; 79:3930-7.
90. Starr-Spires LD, Collman RG: HIV-1 entry and entry inhibitors as therapeutic agents. Clin Lab Med 2002; 22:681-701.
91. Steinberger P, Andris-Widhopf J, Buhler B, Torbett BE, Barbas CF: III. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci U S A 2000; 97:805-10.
92. Steinberger P, Sutton JK, Rader C, Elia M, Barbas CF: III. Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J Biol Chem 2000; 275:36073-8.
93. Stevenson M: Dissecting HIV-1 through RNA interference. Nat Rev Immunol 2003; 3:851-8.
94. Stocks M: Intrabodies as drug discovery tools and therapeutics. Curr Opin Chem Biol 2005; 9:359-65.
95. Stocks PR: Intrabodies: production and promise. Drug Discov Today 2004; 9:960-6.
96. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004; 427:848-53.
97. Stumm RK, Zhou C, Ara T, Lazarini F, Dubois-Dalcq M, Nagasawa T, Hollt V, Schulz S: CXCR4 regulates interneuron migration in the developing neocortex. J Neurosci 2003; 23:5123-30.
98. Swan CH, Bühler BCT, Barbas CFr, Torbett BE: T-Cell protection and enrichment through lentiviral vector CCR5-intrabody gene delivery. Gene Ther 2006; in press.
99. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, Kishimoto T, Nagasawa T: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393:591-4.
100. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 2002; 99:395-400.
101. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, Dable J, Stossel H, Romani N, Piatak M, Jr., Lifson JD, Pope M, Cunningham AL: Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 2004; 103:2170-9.
102. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes MC: Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435:646-51.
103. Valdez H, Purvis SF, Lederman MM, Fillingame M, Zimmerman PA: Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. Jama 1999; 282:734.
104. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006; 20:515-24.
105. Veazey RS, Marx PA, LPckner AA: The mucosal immune system: primary target for HIV infection and AIDS. Trends Immunol 2001; 22:626-33.
106. de Veer MJ, Sledz CA, Williams BR: Detection of foreign RNA: implications for RNAi. Immunol Cell Biol 2005; 83:224-8.
107. Vollweiler JL, Zielske SP, Reese JS, Gerson SL: Hematopoietic stem cell gene therapy: Progress toward therapeutic targets. Bone Marrow Transplant 2003; 32:1-7.
108. Wells TN, Power CA, Shaw JP, Proudfoot AE: Chemokine blockers-therapeutics in the making? Trends Pharmacol Sci 2006; 27:41-7.
109. Westby M, vaH der Ryst E: CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother 2005; 16:339-54.
110. Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, Taylor PA, McKinnon KP, Su L, Blazar BR, Serody JS: Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005; 106:3300-7.
111. Yamagami S, Hamrah P, Miyamoto K, Miyazaki D, Dekaris I, Dawson T, Lu B, Gerard C, Dana MR: CCR5 chemokine receptor mediates recruitment of MHC class II-positive Langerhans cells in the mouse corneal epithelium. Invest Ophthalmol Vis Sci 2005; 46:1201-7.
112. Yang AG, Bai X, Huang XF, Yao C, Chen S: Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci U S A 1997; 94:11567-72.
113. Yi Y, Shaheen F, Collman RG: Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes. J Virol 2005; 79:1480-6.
114. Zaitseva M,RPeden K, Golding H: HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors. Biochim Biophys Acta 2003; 1614:51-61.
115. Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, Weber C: Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: Involvement of IL-10. Blood, 2006; in press.
116. Zielske SP, Lingas KT, Li Y, Gerson SL: Limited lentiviral transgene expression with increasing copy number in an MGMT selection model: Lack of copy number selection by drug treatment. Mol Ther 2004; 9:923-31.
117. Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL: In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest 2003; 112:1561-70.
118. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, Weissman D, Cohen O, Rubbert A, Lam G, Vaccarezza M, Kennedy PE, Kumaraswami V, Giorgi JV, Detels R, Hunter J, Chopek M, Berger EA, Fauci AS, Nutman TB, Murphy PM: Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997; 3:23-36.
119. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393:595-9.